Arcese W, Iori A P, Screnci M, Guglielmi C, Mengarelli A, Carmini D, Testi A M, Moleti M L, Cimino G, Perrone P, Laurenti L, Elia L, Boecklin F, Romano A, De Felice L, Mandelli F
Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy.
Bone Marrow Transplant. 1998 Jun;21 Suppl 3:S85-6.
Twelve consecutive children with high-risk leukemia have been submitted to UCB transplant from unrelated 1 or 2 loci HLA-mismatched donor. All patients received an identical regimen for conditioning and GVHD prophylaxis. The median dose of viable nucleated cells infused was 2.8 x 10(7)/kg bw (range 1.4-7.9). Of 11 patients evaluable for engraftment, the hematopoiesis was of full donor origin in seven patients and autologous in four. The probability of disease-free survival at 1 and 2 years from UCB transplant is 60 and 42%, respectively.
12名患有高危白血病的连续儿童接受了来自1或2个位点HLA不匹配的无关供体的脐血移植。所有患者均接受相同的预处理和移植物抗宿主病预防方案。输注的有活力有核细胞的中位剂量为2.8×10(7)/kg体重（范围1.4 - 7.9）。在11名可评估植入情况的患者中，7名患者的造血功能完全来自供体，4名患者为自体造血。脐血移植后1年和2年的无病生存率分别为60%和42%。
